Brief: Vaxart Announces Positive Preliminary Topline Data From Dose-Ranging Phase 2 Study Of Its Bivalent Norovirus Vaccine Candidate
06/07/2023 14:35
July 6 (Reuters) - Vaxart Inc VXRT.O :
* VAXART ANNOUNCES POSITIVE PRELIMINARY TOPLINE DATA FROM
DOSE-RANGING PHASE 2 STUDY OF ITS BIVALENT NOROVIRUS VACCINE
CANDIDATE
* VAXART INC - CONTINUE TO EXPECT TOPLINE DATA FROM PHASE 2
GI.1
CHALLENGE STUDY IN Q3 2023
* VAXART INC - VACCINE MET ALL PRIMARY ENDPOINTS: VACCINE
WAS
WELL-TOLERATED WITH ROBUST IMMUNOGENICITY
Source text for Eikon: ID:nGNX8fp5yd
Further company coverage: VXRT.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Vaxart
See all newsBrief: Vaxart Expands Intellectual Property Portfolio With European Patent Protecting Proprietary Norovirus Vaccine Technology
Vaxart Q2 revenue falls on lower government contract income
Brief: Vaxart Q2 Net Income USD -13.494 Million
Brief: Vaxart Enters Cooperation Agreement With Stockholder Group And Announces Board And Corporate Governance Enhancements
Vaxart Q1 revenue more than doubles on government contracts